Hsbc Holdings PLC Purchases 55,553 Shares of DaVita Inc. $DVA

Hsbc Holdings PLC raised its position in shares of DaVita Inc. (NYSE:DVA) by 71.7% in the fourth quarter, Holdings Channel reports. The firm owned 133,080 shares of the company’s stock after acquiring an additional 55,553 shares during the quarter. Hsbc Holdings PLC’s holdings in DaVita were worth $15,110,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. Elevation Wealth Partners LLC increased its position in shares of DaVita by 147.3% during the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after acquiring an additional 165 shares in the last quarter. Caitlin John LLC bought a new stake in shares of DaVita in the 4th quarter worth $34,000. Canada Pension Plan Investment Board purchased a new position in shares of DaVita in the second quarter worth $43,000. Sankala Group LLC bought a new position in shares of DaVita during the fourth quarter valued at $39,000. Finally, iSAM Funds UK Ltd bought a new position in shares of DaVita during the third quarter valued at $46,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Trading Down 0.6%

DVA opened at $234.21 on Wednesday. The company’s 50 day moving average is $199.69 and its 200 day moving average is $158.21. The company has a market cap of $15.04 billion, a price-to-earnings ratio of 21.73, a PEG ratio of 0.77 and a beta of 0.88. DaVita Inc. has a 12-month low of $101.00 and a 12-month high of $239.64.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The business had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.36 billion. During the same period last year, the firm earned $2.00 earnings per share. The company’s quarterly revenue was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, analysts predict that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a research report on Monday, June 8th. Zacks Research upgraded shares of DaVita from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. TD Cowen boosted their price objective on shares of DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a report on Monday, May 11th. Barclays raised their target price on shares of DaVita from $158.00 to $194.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Finally, UBS Group lifted their target price on shares of DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $199.17.

Insider Activity

In other news, insider Kathleen Alyce Waters sold 15,405 shares of DaVita stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the transaction, the insider directly owned 109,194 shares of the company’s stock, valued at $22,756,029.60. The trade was a 12.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares of the company’s stock, valued at approximately $25,440,571.40. This trade represents a 27.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 1.50% of the company’s stock.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.